Breast cancer patients exhibiting estrogen receptor (ER)-α expression, with concurrent over-expression of cyclin D1, have been reported not to benefit from treatment with the selective estrogen receptor modulator tamoxifen, which is in contrast to the evident response in ER-α-positive breast cancers with moderate and low cyclin D1 expression [15]. Here, ESR1 is linked to breast cancer.